The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...

Key Takeaways The S&P 500 and Nasdaq reached record highs Monday, while the Dow advanced as well, in the wake of several strong earnings reports.Verizon Communications shares rose after the telecom ...

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

Sarepta Therapeutics shares traded lower in premarket trade on Tuesday, as the drugmaker relented to a Food and Drug ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Sarepta Therapeutics shares plunge over 37% as FDA weighs halting shipments of its key gene therapy, Elevidys, after patient ...

On June 18, TD Cowen downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock to “Hold” from “Buy,” reducing the price objective to $24 from the prior target of $62, as reported by ...

Sarepta Therapeutics (NASDAQ: SRPT) Inc. stock reached a 52-week low, closing at 18.27 USD. This milestone marks a significant downturn for the company, with its stock price experiencing a sharp ...

Investing.com - Piper Sandler maintained its Neutral rating and $36.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) stock following safety concerns with its Duchenne muscular dystrophy (DMD ...